Insider Trading Alert - Smith & Wesson Holding Corporation And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 8, 2013, 58 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.04 to $7,626,400.00.

Highlighted Stocks Traded by Insiders:

Smith & Wesson Holding Corporation (SWHC) - FREE Research Report

Scott Robert L who is Director at Smith & Wesson Holding Corporation sold 1,200 shares at $10.79 on Oct. 8, 2013. Following this transaction, the Director owned 97,834 shares meaning that the stake was reduced by 1.21% with the 1,200 share transaction.

The shares most recently traded at $10.49, down $0.30, or 2.86% since the insider transaction. Historical insider transactions for Smith & Wesson Holding Corporation go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares sold: 8,000

The average volume for Smith & Wesson Holding Corporation has been 2.5 million shares per day over the past 30 days. Smith & Wesson Holding Corporation has a market cap of $726.8 million and is part of the industrial goods sector and aerospace/defense industry. Shares are up 37.44% year to date as of the close of trading on Friday.

Smith & Wesson Holding Corporation engages in the manufacture and sale of firearm products in the United States and internationally. The company has a P/E ratio of 8.7. Currently there are 3 analysts that rate Smith & Wesson Holding Corporation a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWHC - FREE

TheStreet Quant Ratings rates Smith & Wesson Holding Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Smith & Wesson Holding Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Stryker Corporation (SYK) - FREE Research Report

Stryker Ronda E who is Director at Stryker Corporation sold 14,000 shares at $67.74 on Oct. 8, 2013. Following this transaction, the Director owned 11.7 million shares meaning that the stake was reduced by 0.12% with the 14,000 share transaction.

The shares most recently traded at $67.54, down $0.20, or 0.29% since the insider transaction. Historical insider transactions for Stryker Corporation go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 28,000

The average volume for Stryker Corporation has been 1.2 million shares per day over the past 30 days. Stryker Corporation has a market cap of $26.8 billion and is part of the health care sector and health services industry. Shares are up 29.2% year to date as of the close of trading on Friday.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. The stock currently has a dividend yield of 1.5%. The company has a P/E ratio of 23.8. Currently there are 13 analysts that rate Stryker Corporation a buy, 1 analyst rates it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYK - FREE

TheStreet Quant Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Charles River Laboratories International In (CRL) - FREE Research Report

Geller Jorg who is Corporate Executive VP at Charles River Laboratories International In sold 893 shares at $47.17 on Oct. 8, 2013. Following this transaction, the Corporate Executive VP owned 54,192 shares meaning that the stake was reduced by 1.62% with the 893 share transaction.

The shares most recently traded at $46.35, down $0.82, or 1.76% since the insider transaction. Historical insider transactions for Charles River Laboratories International In go as follows:

  • 4-Week # shares sold: 5,958
  • 12-Week # shares sold: 26,805
  • 24-Week # shares sold: 32,825

The average volume for Charles River Laboratories International In has been 353,500 shares per day over the past 30 days. Charles River Laboratories International In has a market cap of $2.3 billion and is part of the health care sector and drugs industry. Shares are up 22.76% year to date as of the close of trading on Friday.

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. The company has a P/E ratio of 22.5. Currently there are 4 analysts that rate Charles River Laboratories International In a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRL - FREE

TheStreet Quant Ratings rates Charles River Laboratories International In as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Charles River Laboratories International In Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Reynolds American (RAI) - FREE Research Report

Brown & Williamson Holdings, Inc. who is 10% Owner at Reynolds American sold 128,365 shares at $49.12 on Oct. 8, 2013. Following this transaction, the 10% Owner owned 227.3 million shares meaning that the stake was reduced by 0.06% with the 128,365 share transaction.

The shares most recently traded at $49.28, up $0.16, or 0.32% since the insider transaction. Historical insider transactions for Reynolds American go as follows:

  • 4-Week # shares sold: 257,366
  • 12-Week # shares sold: 1.1 million
  • 24-Week # shares sold: 2.6 million

The average volume for Reynolds American has been 1.5 million shares per day over the past 30 days. Reynolds American has a market cap of $27.0 billion and is part of the consumer goods sector and tobacco industry. Shares are up 19.6% year to date as of the close of trading on Friday.

Reynolds American Inc., through its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. The company operates through RJR Tobacco, American Snuff, and Santa Fe segments. The stock currently has a dividend yield of 5.09%. The company has a P/E ratio of 18.0. Currently there are 2 analysts that rate Reynolds American a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RAI - FREE

TheStreet Quant Ratings rates Reynolds American as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Reynolds American Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Terex (TEX) - FREE Research Report

Lousberg Kenneth D. who is President, Terex China at Terex bought 51 shares at $34.03 on Oct. 8, 2013. Following this transaction, the President, Terex China owned 67,254 shares meaning that the stake was reduced by 0.08% with the 51 share transaction.

The shares most recently traded at $34.38, up $0.35, or 1.02% since the insider transaction. Historical insider transactions for Terex go as follows:

  • 4-Week # shares bought: 356
  • 4-Week # shares sold: 12,000
  • 12-Week # shares bought: 2,704
  • 12-Week # shares sold: 60,263
  • 24-Week # shares bought: 3,872
  • 24-Week # shares sold: 79,013

The average volume for Terex has been 1.9 million shares per day over the past 30 days. Terex has a market cap of $3.8 billion and is part of the industrial goods sector and industrial industry. Shares are up 20.99% year to date as of the close of trading on Friday.

Terex Corporation operates as an equipment manufacturer of specialized machinery products. The company has a P/E ratio of 103.1. Currently there are 7 analysts that rate Terex a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TEX - FREE

TheStreet Quant Ratings rates Terex as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and poor profit margins. Get the full Terex Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker